Leqvio (Inclisiran) HSA/FSA Eligibility and How to Pay Less for Your Injections

Is Leqvio an HSA/FSA-Eligible Expense?

Yes, Leqvio is eligible for reimbursement from a Health Savings Account (HSA) or Flexible Spending Account (FSA). The IRS classifies prescription drugs as qualified medical expenses under IRS Publication 502, and inclisiran is a prescription-only medication administered by a licensed clinician. That means your out-of-pocket cost after insurance, or the full cost if you are uninsured, can be paid with tax-advantaged HSA or FSA dollars.

There is one practical wrinkle: Leqvio is not dispensed at a retail pharmacy and picked up by you. It is given by injection in a clinical setting, typically every six months after the loading period. That changes how you collect documentation, and it is where most women run into submission problems.

What the IRS Actually Requires

The IRS requires that the expense be for a prescription medication diagnosed and ordered for a specific individual. Because Leqvio is used to lower LDL cholesterol in adults with established cardiovascular disease or heterozygous familial hypercholesterolemia (HeFH), it clearly meets this threshold. What your plan administrator needs to see is an itemized receipt, not just a credit card statement or explanation of benefits.

What "Itemized" Means for a Clinician-Administered Drug

For an infusion-center or office-administered drug like Leqvio, your itemized receipt or superbill should include:

• The drug's full name (inclisiran or Leqvio)
• The NDC (National Drug Code) or HCPCS billing code (J-code)
• The date of service
• The name and NPI of the administering clinician or facility
• The exact dollar amount you paid out of pocket
• The patient's name (yours)

Your cardiology or lipid clinic's billing department can generate this. Ask for it at the time of your appointment, or request it within 30 days so it does not get buried.

How to Submit an HSA or FSA Claim for Leqvio

Submission steps vary slightly by plan administrator, but the core process is consistent.

Step 1: Collect Your Documentation

Request an itemized receipt or superbill from the clinic where you receive each injection. If Leqvio is billed through a specialty pharmacy that ships to the clinic (a common arrangement called "buy-and-bill"), ask the pharmacy for a receipt that includes the drug name, quantity, and your cost share.

Step 2: Log Into Your HSA or FSA Portal

Most plans use platforms such as HealthEquity, Optum Financial, Fidelity HSA, or WageWorks (now Inspira Financial). Upload your receipt as a PDF or image. Some platforms let you pay the clinic directly if they are in-network with the plan, bypassing manual reimbursement.

Step 3: Submit a Reimbursement Request

Fill in the expense category as "Prescription Drug" or "Medical Expense." Enter the amount you paid. Attach your itemized documentation. Processing typically takes five to ten business days.

Step 4: Keep Records for Three Years

The IRS can audit HSA withdrawals up to three years after the filing year. Store your itemized receipts digitally and separately from general financial records.

The Real Cost of Leqvio and Why Access Is Complicated

Leqvio carries a list price of roughly $3,500 to $4,000 per injection as of early 2026. Because the standard schedule means two injections in the first year and then one injection every six months, annual treatment costs can reach $10,000 to $16,000 at list price before any insurance adjustment. That price point creates access barriers that disproportionately affect women in specific life situations, including those who are uninsured, on high-deductible health plans, or in the coverage gap between Medicaid income limits and employer insurance.

The ORION-11 trial, which was the key Phase 3 study supporting Leqvio's FDA approval in December 2021, found that inclisiran lowered LDL-C by approximately 50% compared with placebo at 510 days in patients with established cardiovascular disease or HeFH. Women comprised about 27% of the ORION-11 population, a figure that reflects the longstanding under-representation of women in cardiovascular trials. The efficacy signal in women was directionally consistent with men, but the trial was not powered to detect sex-specific differences in hard outcomes.

How to Get Leqvio Cheaper: Every Available Pathway

Commercial Insurance and Prior Authorization

Most commercial insurers require prior authorization (PA) before covering Leqvio. Your prescriber typically submits clinical documentation showing that you have established atherosclerotic cardiovascular disease (ASCVD) or HeFH and that you have either tried or have a contraindication to maximally tolerated statins. ACC/AHA guidelines recommend PCSK9-targeting therapies as add-on treatment when LDL remains above goal despite statins and ezetimibe.

If your PA is denied, appeal immediately. First-level appeals succeed in a significant proportion of lipid-lowering drug denials, particularly when your clinician documents cardiovascular risk quantitatively.

The Leqvio Together Patient Support Program

Novartis operates "Leqvio Together," a patient support program that includes copay assistance for commercially insured patients. Eligible patients may pay as little as $0 per month in copay costs, though income limits and insurance requirements apply and program terms change frequently. Check the current terms directly through your prescriber's office or the Novartis support line, because the copay card structure was updated in 2025 and may change again.

Leqvio Together also provides injection site coordination assistance, which matters because Leqvio cannot be self-administered. A nurse or navigator can help you locate a participating administration site if your primary cardiology office does not administer it on-site.

Medicare Part D

Medicare Part D covers Leqvio for qualifying beneficiaries. Coverage tier placement varies by plan, but the 2025 introduction of the $2,000 out-of-pocket cap under the Inflation Reduction Act significantly changed the math for Medicare beneficiaries. Women 65 and older, the demographic with the highest absolute cardiovascular event risk, may find Medicare Part D substantially more affordable in 2026 than in prior years. If your plan's formulary places inclisiran on Tier 4 or 5, your prescriber can request a formulary exception citing the ACC/AHA guidelines.

Medicaid

Medicaid coverage varies by state. As a specialty medication, inclisiran is subject to PA requirements in most state Medicaid programs. Some states cover it for HeFH patients but not for ASCVD-only indications. Your prescriber's office or a Novartis case manager can run a real-time benefits check.

The WomanRx Life-Stage Access Framework for Leqvio:

| Life Stage | Primary Coverage Path | Key Access Consideration | |---|---|---| | Reproductive years (with ASCVD or HeFH) | Commercial insurance + copay card | Contraception requirement while on drug; PA often requires documentation of prior statin trial | | Perimenopause | Commercial insurance or Medicare transition | LDL often rises with estrogen decline; may be first time PCSK9 therapy is considered | | Post-menopause (<65) | Commercial insurance + Leqvio Together | Most studied population; strongest PA approval rate | | Post-menopause (Medicare eligible) | Medicare Part D + Inflation Reduction Act cap | $2,000 annual OOP cap may make this the most affordable window | | Uninsured | Novartis patient assistance program | Income-based; apply before starting treatment |

Sex-Specific Physiology: What Women Need to Know About Inclisiran

Inclisiran works differently from statin drugs. It is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA in liver hepatocytes, reducing PCSK9 protein synthesis and keeping LDL receptors active longer. The mechanism is the same regardless of sex, but several considerations are female-specific.

LDL Patterns Across the Female Lifespan

LDL cholesterol in women follows a hormone-influenced trajectory. During the reproductive years, estrogen generally maintains a more favorable lipid profile compared with age-matched men. At perimenopause, as endogenous estrogen declines, LDL can rise by 10 to 14 mg/dL on average, according to data from the Study of Women's Health Across the Nation (SWAN). This means that some women who were at-goal on statin monotherapy during their 40s may find themselves above LDL targets in their 50s, making the addition of a PCSK9 inhibitor relevant for the first time.

Post-menopause is the period when most women will genuinely need inclisiran, and it is also when Medicare eligibility approaches, making the cost question particularly acute.

PCOS and Lipid Risk

Women with polycystic ovary syndrome (PCOS) have a higher prevalence of atherogenic dyslipidemia, including elevated LDL and triglycerides, compared with women without PCOS, as documented in a 2020 meta-analysis in Human Reproduction Update. If you have PCOS and established ASCVD or HeFH, inclisiran may be relevant earlier in life than it would be for a typical woman. The evidence base for inclisiran specifically in PCOS patients is currently limited to extrapolation from the general HeFH and ASCVD trial populations.

Familial Hypercholesterolemia in Women

HeFH affects approximately 1 in 250 people, and because it is autosomal dominant, women are affected at the same frequency as men. Women with HeFH who are in the reproductive years face the additional complexity of managing severely elevated LDL through pregnancy, when most lipid-lowering drugs are contraindicated. Inclisiran is not used during pregnancy (see the section below), but identifying HeFH before or between pregnancies is critical so a treatment plan can be in place.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting Leqvio

Inclisiran is contraindicated in pregnancy. This is not a precautionary label added for legal coverage. Cholesterol is a required substrate for fetal steroidogenesis, placental development, and cell membrane synthesis. Drugs that significantly lower maternal cholesterol, including PCSK9 inhibitors as a class, carry a theoretical risk of fetal harm, and animal reproduction studies with inclisiran showed fetal toxicity at doses relevant to human exposure.

FDA Pregnancy Category and Human Data

Inclisiran does not have a traditional letter pregnancy category because it was approved under the post-2015 Pregnancy and Lactation Labeling Rule (PLLR). The FDA prescribing information for Leqvio states that inclisiran should not be used during pregnancy, that women of childbearing potential should be counseled about the risk, and that human data are insufficient to establish safety. There are no controlled trials in pregnant women, and none are planned or ethical to conduct.

How Long Does Inclisiran Stay Active?

This is an important question for women of reproductive age. Inclisiran has a plasma half-life of approximately nine hours, but its pharmacodynamic effect on LDL lasts far longer because the siRNA is incorporated into hepatocytes and continues silencing PCSK9 mRNA for months. The LDL-lowering effect persists for roughly six months per dose, which aligns with the dosing schedule. If you are planning a pregnancy, discuss with your clinician how far in advance you should stop inclisiran. Current guidance does not specify a validated washout period, but the six-month dosing interval provides a practical reference: most clinicians advise stopping at least one full dosing cycle before attempting conception.

Contraception Requirements

Because of the teratogenic potential and the long pharmacodynamic duration, women of reproductive potential who are prescribed inclisiran should use reliable contraception. If you use hormonal contraception, inclisiran does not appear to significantly interact with oral contraceptives based on current pharmacokinetic data, but confirm this with your prescriber because the data set is small.

Lactation

Inclisiran's transfer into human breast milk has not been studied. The FDA label advises against use during breastfeeding. Because inclisiran is a large RNA molecule, gastrointestinal absorption from breast milk is expected to be minimal, but systemic exposure in infants has not been measured. If you are postpartum and breastfeeding and have a pressing need for aggressive LDL lowering, discuss the risk-benefit balance with your clinician. Statins, which are better characterized in terms of lactation transfer, are also generally avoided during breastfeeding.

Who Is a Good Candidate for Leqvio, and Who Is Not

Likely Appropriate Candidates

• Women with established ASCVD (prior MI, stroke, or peripheral artery disease) whose LDL remains above goal on maximally tolerated statin plus ezetimibe
• Women with heterozygous familial hypercholesterolemia, regardless of prior cardiovascular events, when LDL target is not met on oral therapy
• Women who cannot tolerate statins due to myopathy and who have a strong cardiovascular risk indication
• Postmenopausal women whose LDL rose significantly after estrogen decline and who have failed oral add-on therapies
• Women on Medicare Part D in 2026 who benefit from the $2,000 out-of-pocket cap

Generally Not Appropriate

• Women who are pregnant or planning pregnancy in the next six to twelve months
• Women who are breastfeeding
• Women whose LDL is at goal on current therapy (adding inclisiran provides no incremental benefit)
• Women with premenopausal risk profiles who do not have HeFH or established ASCVD (the absolute cardiovascular risk reduction is small when baseline risk is low)
• Women who have not yet tried a statin and ezetimibe combination (insurers require documented prior therapy, and clinical guidelines support this sequencing)

Practical Tips for Navigating the Leqvio Access Process as a Woman

Working through PA requirements and cost programs can feel like a second job. A few steps that make a concrete difference:

Ask your cardiology or lipid clinic if they have a specialty pharmacy coordinator. Practices that prescribe significant volumes of Leqvio often have staff whose job is handling PA submissions and copay card enrollment. You should not have to do this alone.

Get your prior cardiovascular event and LDL history in writing. PA reviewers want documentation of: current LDL level, LDL goal, statin history (drug, dose, duration), and reason for any statin discontinuation. Having this ready before submission shortens the timeline.

Time your HSA/FSA claim to your plan year. FSA funds may be use-it-or-lose-it by December 31 depending on your employer's grace period election. If your injection falls in December, submit the claim before year-end even if you have not received the reimbursement.

If you are in the Medicare donut hole, check timing. Under the 2026 Part D structure with the $2,000 cap, most women will not reach catastrophic coverage, but confirm your plan's specific tier and formulary quarterly since formularies change January 1.

Document every denial and appeal date. If you file an external appeal through your state insurance commissioner, the clock starts from the denial date. Missing the deadline forfeits your right to external review.

What the Evidence Gap Means for You

Women made up approximately 27% of ORION-11 participants and roughly 30% of patients across the broader ORION trial program. That is a meaningful under-representation given that women have a lifetime cardiovascular risk that equals or exceeds men's after age 65, and that post-menopausal women represent one of the largest groups who might benefit from inclisiran. The trial results are directionally applicable, but exact effect size estimates, optimal timing of treatment initiation relative to menopause, and long-term safety in women across the lifespan have not been studied with adequate statistical power for sex-stratified conclusions. Your clinician is extrapolating from majority-male data when recommending inclisiran, and that is worth knowing.

Dr. Maya Okafor, MD, a women's health and cardiovascular medicine specialist on the WomanRx editorial board, notes: "The 50% LDL reduction we see with inclisiran is clinically meaningful, but the field still owes women a properly powered sex-stratified outcomes trial. Until we have that data, we use the best available evidence and apply it thoughtfully, with particular attention to each woman's hormonal context and life stage."

Frequently Asked Questions